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Abstract: Hyper-insulinemia euglycemia therapy (HIET) is a supra-physiological insulin dosing protocol 
used in acute cardiac failure to reduce dependency on inotropes to augment or generate cardiac output, 
and is based on the inotropic effects of insulin at high doses up to 45-250x normal daily dose. Such high 
insulin doses are managed using intravenous glucose infusion to control glycemia and prevent 
hypoglycemia. However, both insulin dosing and glycemic control in these patients is managed ad-hoc. 
This research examines a selection of clinical data to determine the effect of high insulin dosing on renal 
clearance and insulin sensitivity, to assess the feasibility of using model-based methods to control and 
guide these protocols. The results show that the model and, in particular, the modeled renal clearance 
constant are adequate and capture measured data well, although not perfectly. Equally, insulin sensitivity 
over time is similar to broader critical care cohorts in level and variability, and these results are the first 
time they have been presented for this cohort. While more data is needed to confirm and further specify 
these results, it is clear that the model used is adequate for controlling HIET in a model-based 
framework. 
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
1. INTRODUCTION 
Insulin has beneficial effects on cardiac function in very high 
doses (Ouwens and Diamant 2007; Massion and Preiser 
2010). Hyper-Insulinemia Euglycemia Therapy (HIET) 
combines these insulin effects to treat patients with 
postoperative cardiogenic shock. In particular, high dosing of 
insulin of ~1 U/kg/hour, which for an 80kg individual is ~45x 
the normal daily dose, has shown significant inotropic action 
in reducing the need for inotropes and reinstating cardiac 
function in cases of severe cardiac failure (Boyer, Duic et al. 
2002; Massion and Preiser 2010). 
Such high doses of insulin are managed via exogenous 
glucose infusions, to avoid severe hypoglycemia. However, 
insulin dosing protocols or rules during HIET are still 
empirical, as effect varies. Doses have been recommended 
between 0.5-6.0U/kg/hour (Boyer, Duic et al. 2002; Massion 
and Preiser 2010). However, all of these levels are very high 
and significantly hypoglycemic. Thus, there is a need for a 
careful protocol to administer insulin to titrate inotropic 
effect while safely managing BG levels via exogenous 
glucose infusion, where it should be noted that glucose 
infusions that are too high can also have negative effect over 
30-50 g/hour delivered (Ichai, Cariou et al. 2009). Hence, the 
problem is one of dosing insulin for one outcome and 
controlling glycemia with a peak limited infusion of 
exogenous glucose. 
This work aims to develop a model-based glycemic controller 
to capture the patient-specific response and safely optimize 
HIET interventions. Such model-based controllers have 
shown significant success in controlling glycemia in highly 
insulin resistant critically ill patients (Plank, Blaha et al. 
2006; Evans, Shaw et al. 2011; Penning, Le Compte et al. 
2011). Importantly, several of these controllers use both 
insulin and nutrition to control glycemia, where nutritional 
control elements are critical to this problem (Chase, Shaw et 
al. 2008; Evans, Shaw et al. 2011; Penning, Le Compte et al. 
2011).  
Notably such high insulin doses can be controlled without 
significant increase in nutrition rate. Typically, for 40-50x the 
normal daily dose of insulin, glucose administration increases 
only approximately to 2x normal. Hence, there is evidence of 
significant insulin saturation effects, which have also been 
observed in critically ill glycemic control and other normal 
individuals (Prigeon, Roder et al. 1996; Natali, Gastaldelli et 
al. 2000; Lin, Razak et al. 2011).  
The first step is to determine whether a validated glucose-
insulin system model (Chase, Suhaimi et al. 2010; Lin, Razak 
et al. 2011) has to be adapted for the very high insulin doses 
(~1UI/kg/h) in HIET. Specifically, do such large doses have 
different apparent kinetics? The characterization of patient-
specific renal clearance is also an essential feature for an 
accurate physiological understanding of insulin kinetics at 
this dosing level. Finally, insulin sensitivity varies 
significantly in the critically ill, both inter-patient and, over 
30-60 minutes, intra-patient (Lin 2006; Lin, Lee et al. 2008), 
and the time course of insulin sensitivity at these dosing 
levels and for these patients has never been reported 
previously, which will also aid understanding of the 
physiological mechanisms. 
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Specifically, the research presented thus tries to answer 3 
main questions: 
 
 Is the glucose-insulin system model able to capture 
HIET patient behaviour? 
 Should the insulin clearance modelling be modified 
for high insulin doses? In particular, renal clearance 
may be nonlinear at very high concentration as other 
renal clearance mechanisms can occur. 
 Is the insulin sensitivity of HIET patients 
physiological or affected by modelling of high 
insulin doses? 
In developing these answers, the research examines unique 
clinical data developed from two initial patients on an HIET 
protocol. The data includes full insulin and BG data to enable 
model-based analysis of all these questions. The main goal is 
to derive a first understanding of the answers to these 
questions to drive and inform future patients and studies. 
 
2. METHODS 
2.1 Patients and Data 
This overview analysis is based on clinical data from 2 
patients included in a HIET protocol from January 2011 in 
the intensive care units (ICU) at the Centre Hospitalier 
Universitaire (CHU) de Liège, Belgium. Ethical approval was 
obtained from the Ethics Committee of the Medical Faculty 
of the University of Liege (Belgium). 
Clinical data measurements are blood glucose (BG) levels, 
exogenous insulin infusions, plasma insulin concentrations 
and exogenous glucose inputs (enteral and parenteral 
nutrition, medications and glucocorticoids). BG levels 
measurements were made using Accu-Check Inform (Roche 
Diagnostics, Mannheim, Germany) glucometers and plasma 
insulin concentrations were measured using the hexokinase 
method (Modular P, Roche Diagnostics, Mannheim, 
Germany).  
The general characteristics of the two first patients who 
received HIET are summarized in Table 1.  
 
Table 1: Characteristics of HIET patients. 
 Patient 1 (P1) Patient 2 (P3) 
Sex  F F 
Date of birth 16/04/1963 13/06/1949 
Weight (kg) 72 56 
Diagnosis Aortic valve 
replacement 
Coronary Artery Bypass 
Graft Surgery 
Mitral valve 
replacement 
Diabetic status No No 
ICU day when 
HIET started 
1 2 
Length HIET, in 
min (in hours) 
2880 (48h) 3120 (52h) 
Number of BG 
measurements 
36 25 
Initial BG 
(mg/dL) 
151 174 
Median BG [IQR] 
(mg/dL) 
119.5 [99.5 - 139.5] 130.0 [114.8 - 152.0] 
% BG within 80-
140 mg/dL 
66.7 72 
% BG < 80 mg/dL 8.3 0 
% BG < 72 mg/dL 0.0 0.0 
Median insulin 
rate [IQR] (U/h) 
35.0 [35.0 - 70.0] 30.0 [30.0 - 59.0] 
Max insulin rate 
(U/h) 
70.4 60.0 
Median dextrose 
rate [IQR] (g/h) 
25.0 [25.0 - 25.0] 26.0 [20.0 - 26.0] 
 
2.2 Glucose-insulin system model 
The glucose-insulin system model used is defined by 
Equations (1)-(5) (Lin, Razak et al. 2011). 
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G(t) and I(t) [mU/L] is the plasma insulin, exogenous insulin 
input is represented by u(t) [mU/min]. Interstitial insulin is 
represented by Q(t) [mU/L], with nI [1/min] accounting for 
the rate of transport between plasma and interstitial insulin 
compartments. Endogenous insulin production is estimated 
with uen [mU/min] modeled as a function of blood glucose 
concentration determined from critical care patients with a 
minimum pancreatic output of 1U/hr. First-pass hepatic 
insulin clearance is represented by xL. Patient endogenous 
glucose clearance and insulin sensitivity are pG [1/min] and SI 
[L/(mU.min)], respectively. The parameter VI [L] is the 
insulin distribution volume and nK [1/min] and nL [1/min] 
represent the clearance of insulin from plasma via renal and 
hepatic routes respectively. Basal endogenous glucose 
production unsuppressed by glucose and insulin 
concentration is denoted by EGPb [mmol/min] and VG [L] 
represents the glucose distribution volume. CNS [mmol/min] 
represents non-insulin mediated glucose uptake by the central 
nervous system. Michaelis-Menten functions are used to 
model saturation, with αI [L/mU] used for the saturation of 
plasma insulin clearance by the liver, and αG [L/mU] for the 
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saturation of insulin-dependent glucose clearance and 
receptor-bound insulin clearance from the interstitium. P1 
[mmol] represents the glucose in the stomach and P2 [mmol] 
represents glucose in the gut. The rate of transfer between the 
stomach and gut is represented by d1 [1/min], and the rate of 
transfer from the gut to the bloodstream is d2 [1/min]. Enteral 
glucose input is denoted P(t) [mmol/min], and Pmax represents 
the maximum disposal rate from the gut. The constants used 
in (1) to (5) are shown in Table 2.  
 
Table 2: Numerical values of model parameters 
Model variable 
Numerical value (or typical range of 
values) 
    0.006 min
-1 
    [1x10
-7
 – 1x10-2] L/(mU.min) 
    1/65 L/mU
 
    -ln(0.5)/20 
    -ln(0.5)/100 
      6.11 mmol/min 
      1.16 mmol/min typically 
     0.3 mmol/min 
    13.3 L 
       0.006 min
-1 
    1.7x10
-3
 L/mU 
    4.0 L 
    0.67 
    0.0542 min
-1 
    0.1578 min
-1 
 
2.3 Evolution of renal insulin clearance over time 
Hepatic insulin clearance saturates at high insulin doses 
whereas renal insulin clearance does not (Koschorreck and 
Gilles 2008). Therefore, it is hypothesised that only renal 
clearance processes can be modified or different for HIET 
patients. More specifically, only renal clearance has the 
ability to become large enough to potentially affect clearance 
and plasma insulin levels at such large doses.  
This modification implies a change of the    parameter value 
in Equation (2). To study the possible change of renal 
clearance, the relationship between    and insulin data 
(plasma I, interstitial Q and exogenous      insulin) can be 
derived. This relation can be obtained by rearranging 
Equation (2) to read: 
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Approximations (piecewise linear interpolation) of 
 ( )    ( )     ( )  ( )  (̇ )  ( ) can be obtained from 
clinical data using the approach outlined in Figure 1, and are 
used to calculate   ( ), using Equation (6). Equation (7) is 
used to define    ( ): 
   ( )      (   (     (      ( )      ))       ) (7) 
 
Figure 1: Determination of model variables from clinical data. 
 
2.4 Analysis  
From patient clinical data,  ( ) can be approximated using 
piecewise linear interpolation and Equations (2) and (3) of 
the model can be solved to simulate the evolution of plasma 
 ( ) and interstitial  ( ) insulin concentrations. Simulated 
 ( ) evolution can then be compared to clinical plasma 
insulin measurements to assess model accuracy and the need 
for greater or lesser renal clearance.  
Insulin sensitivity (SI) in the model accounts for evolving 
physiological patient condition and intra-patient variability. It 
is an overall measure of whole body insulin sensitivity and 
metabolic balance. Patient specific profiles of insulin 
sensitivity (SI) can be obtained using the method of Hann et 
al. (Hann, Chase et al. 2005). These profiles can be compared 
to clinical results over 371 critically ill patients of all types 
(Lin 2006; Lin, Lee et al. 2008) to ascertain whether they are 
within normal bounds or affected by the supra-physiological 
dosing used here.  
 
3. RESULTS and DISCUSSION 
Measured and simulated plasma insulin concentration seems 
to correspond well for Patients 1 and 2. These results are 
presented in Figure 2 for both patients.  
 
 
Figure 2: Results of insulin-glucose simulation for patients 1 (top) and 2 
(bottom). For each patient, from top to bottom graphs: first panel = BG 
measurements (crosses) and linear fitting (mg/dL); second panel = 
measured   (crosses), and simulated  ( ) (in red) and  ( ) (in blue) 
(mU/L); third panel = insulin infusions (U/h); last panel = exogenous 
dextrose inputs (g/h), enteral (in blue) and parenteral (in red) nutrition. 
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These results indicate that the model is able to reproduce 
insulin kinetics for HIET patients and doses. Patient 2 
presents a relatively high plasma insulin concentration at 
t=8h, which is likely erroneous given the dosing and 
surrounding measurements. 
Figure 3 shows that patient insulin sensitivity is quite 
variable over HIET as might be expected (Lin, Lee et al. 
2008). These levels are within normal levels observed in the 
critically ill. The variability is also within observed 
boundaries. Hence, the insulin sensitivity profiles are not 
affected by the supra-physiological dosing used, which is also 
a further validation of the models and methods. 
 
 
Figure 3: Results of model simulation and insulin sensitivity (L/mU.min) 
identification for Patients 1 (top) and 2 (bottom). 
 
Analysis of the renal clearance parameter,   , is mixed. 
Patient 1 results seem to indicate that the default    value 
under-estimates insulin clearance, whereas Patient 3 results 
appear to indicate that the default    value over-estimates 
insulin clearance. These results are outlined in Figure 4. Note 
that the default renal clearance value is set at an approximate 
glomerular filtration rate (GFR) for renal clearance and does 
not account for supra-physiological levels or added clearance 
from tubule excretion (Moran and Myers 1985; Lamb, 
Tomson et al. 2005). 
What is interesting to note is that the constant rate at an 
approximate GFR is largely accurate for both patients over 
much of their stay. However, at some insulin dosing levels it 
appears that GFR can be underestimated by a factor of 2. 
Similarly, the model-based analysis, also for Patient 2, shows 
a shorter period of overestimation of 100%. Similarly, Patient 
3 consistently is consistently overestimated by 20-50%, or a 
factor of 0.5-0.8x lower than the default GFR value. 
Overall, these results suggest two main outcomes for the 
analysis of renal clearance at supra-physiological insulin 
dosing levels for these patients: 
 The GFR approximation is not significantly in error, 
or at least, that very high insulin doses do not affect 
renal clearance enough that it should be significantly 
modified based on this limited data and analysis 
 Renal clearance appears to be time varying in nature 
in these patients. This outcome is not at all 
unexpected as renal clearance and failure are very 
common in critically ill patients (Hoste, Lameire et 
al. 2003; Bentley 2011). Thus, a time varying value 
is not unexpected 
Overall, these results are supportive of the current value until 
further patients and data are collected. Certainly, there is no 
reason to change the value in modeling insulin levels in these 
patients using the ICING model of Equations (1)-(5) (Lin, 
Razak et al. 2011).  
Given that renal clearance is not readily identifiable at the 
bedside in real time and that typical creatinine clearance 
methods and formulas have very high errors (Bjornsson 
1979; Moran and Myers 1985; Froissart, Rossert et al. 2005), 
the current assumptions may not be perfect. However, 
clinically, for application in a model-based protocol the 
results are indicative that the model is acceptable for this 
purpose going forward with more patients and creating a 
model-based protocol. 
 
 
Figure 4: Results of renal clearance parameter for Patients 1 (top) and 2 
(bottom). For each patient, from top to bottom graphs: first panel = BG 
measurements and linear piece-wise interpolation (mg/dL); second panel 
=    evolution over time (dashed line) and    default value (0.0542) 
(     ); third panel =    as a function of  ; last panel = exogenous 
insulin infusions (U/h). 
 
Thus, the answers to the main questions posed have all been 
answered in this initial study. Specifically: 
 The glucose-insulin ICING system model of 
Equations (1)-(5) is well able to capture HIET 
patient behaviour and dynamics of both glucose and 
insulin at supra-physiological dosing levels 
 The insulin clearance modelling and constant do not 
need to be modified for high insulin doses. This 
result is perhaps surprising and should be confirmed 
by further patients. However, it will provide much 
more certainty in protocol design and model-based 
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analysis. However, it does appear that this clearance 
may be nonlinear or at least time-varying, as 
expected in critically ill cohorts. 
The insulin sensitivity profile of HIET patients was the same 
or similar to those observed in broader cohorts of critically ill 
patients in both level and variability. 
All these results validate the overall methods and models 
taken to start this research into HIET patients and protocols, 
as well as acting as further specific validation of the ICING 
metabolic system model. 
 
4. CONCLUSIONS 
The model of the glucose-insulin system is able to reproduce 
insulin kinetics for HIET patients and high insulin doses. 
Renal insulin clearance modeling appears adequate but 
requires further data to confirm this result. Overall, the 
models and methods presented are further validated for the 
primary goal of creating model-based methods of managing 
this treatment and these patients. The results and outcomes 
also provide unique results and insight into the metabolic 
behavior of patients who have severe cardiac failure and are 
supra-physiologically dosed with insulin. 
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